Illinois General Assembly - Full Text of HR0705
Illinois General Assembly

Previous General Assemblies

Full Text of HR0705  102nd General Assembly




HR0705LRB102 26364 MST 36527 r


2    WHEREAS, Many peoples with serious, chronic mental
3illness, such as schizophrenia and other schizoaffective
4disorders, bipolar disorder, or severe depression, require
5treatment with medications that work as dopamine receptor
6blocking agents (DRBAs), including antipsychotics; and
7    WHEREAS, While ongoing treatment with these medications
8can be very helpful and even lifesaving, for many people, it
9can also lead to Tardive Dyskinesia (TD); and
10    WHEREAS, Many people who have gastrointestinal disorders,
11including gastroparesis, nausea, and vomiting, also require
12treatment with DRBAs; and
13    WHEREAS, Treatment of gastrointestinal disorders with
14DRBAs can be very helpful, but for many patients, it can lead
15to Tardive Dyskinesia; and
16    WHEREAS, Tardive Dyskinesia is a movement disorder that is
17characterized by random, involuntary, and uncontrolled
18movements of different muscles in the face, trunk, and
19extremities; in some cases, people may experience movement of
20the arms, legs, fingers, and toes; it may affect the tongue,
21lips, and jaw; symptoms may include swaying movements of the



HR0705- 2 -LRB102 26364 MST 36527 r

1trunk or hips and may impact the muscles associated with
2walking, speech, eating, and breathing; and
3    WHEREAS, Tardive Dyskinesia can develop months, years, or
4decades after a person starts taking DRBAs and even after they
5have discontinued use of those medications; not everyone who
6takes a DRBA develops TD, but if it develops, it is often
7permanent; and
8    WHEREAS, Common risk factors for Tardive Dyskinesia
9include advanced age and alcoholism or other substance abuse
10disorders; postmenopausal women and people with a mood
11disorder are also at higher risk of developing Tardive
12Dyskinesia; and
13    WHEREAS, A person is at higher risk for TD after taking
14DRBAs for three months or longer, but the longer the person is
15on these medications then the higher the risk of developing
16Tardive Dyskinesia; and
17    WHEREAS, Studies suggest that overall risk of developing
18Tardive Dyskinesia is between 10 and 30 percent; and
19    WHEREAS, It is estimated that over 600,000 Americans
20suffer from Tardive Dyskinesia; according to the National
21Alliance for Mental Illness, one in every four patients



HR0705- 3 -LRB102 26364 MST 36527 r

1receiving long-term treatment with an antipsychotic medication
2will experience Tardive Dyskinesia; and
3    WHEREAS, Years of difficult and challenging research have
4resulted in recent scientific breakthroughs, with two new
5treatments for Tardive Dyskinesia approved by the United
6States Food and Drug Administration; and
7    WHEREAS, Tardive Dyskinesia is often unrecognized, and
8patients suffering from the illness are commonly misdiagnosed;
9regular screening for TD in patients taking DRBA medications
10is recommended by the American Psychiatric Association (APA);
12    WHEREAS, Patients suffering from Tardive Dyskinesia often
13suffer embarrassment due to abnormal and involuntary
14movements, which leads them to withdraw from society and
15increasingly isolate themselves as the disease progresses; and
16    WHEREAS, Caregivers of patients with Tardive Dyskinesia
17face many challenges and are often responsible for the overall
18care of the TD patient; and
19    WHEREAS, The Legislature can raise awareness of Tardive
20Dyskinesia in the public and in the medical community;
21therefore, be it



HR0705- 4 -LRB102 26364 MST 36527 r

3we declare the week of May 1, 2022 as "Tardive Dyskinesia
4Awareness Week" in the State of Illinois; and be it further
5    RESOLVED, That we encourage the citizens of Illinois to
6become better informed about Tardive Dyskinesia.